PURPOSE: Engaging primary care providers (PCPs) in BRCA1/2 testing and results disclosure would increase testing access. The BRCA Founder OutReach (BFOR) study is a prospective study of BRCA1/2 founder mutation screening among individuals of Ashkenazi Jewish descent that sought to involve participants' PCPs in results disclosure. We used quantitative and qualitative methods to evaluate PCPs' perspectives, knowledge, and experience disclosing results in BFOR. METHODS: Among PCPs nominated by BFOR participants to disclose BRCA1/2 results, we assessed the proportion agreeing to disclose. To examine PCP's perspectives, knowledge, and willingness to disclose results, we surveyed 501 nominated PCPs. To examine PCPs' experiences disclosing results in BFOR, we surveyed 101 PCPs and conducted 10 semi-structured interviews. RESULTS: In the BFOR study overall, PCPs agreed to disclose their patient's results 40.5% of the time. Two hundred thirty-four PCPs (46.7%) responded to the initial survey. Responding PCPs were more likely to agree to disclose patients' results than non-responders (57.3% vs. 28.6%, p<0.001). Among all respondents, most felt very (19.7%) or somewhat (39.1%) qualified to share results. Among PCPs declining to disclose, insufficient knowledge was the most common reason. In multivariable logistic regression, feeling qualified was the only variable significantly associated with agreeing to disclose results (OR 6.53, 95% CI 3.31, 12.88). In post-disclosure surveys (response rate=55%), PCPs reported largely positive experiences. Interview findings suggested that although PCPs valued the study-provided educational materials, they desired better integration of results and decision support into workflows. CONCLUSION: Barriers exist to incorporating BRCA1/2 testing into primary care. Most PCPs declined to disclose their patients' BFOR results, although survey respondents were motivated and had positive disclosure experiences. PCP training and integrated decision support could be beneficial. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03351803), November 24, 2017.
PURPOSE: Engaging primary care providers (PCPs) in BRCA1/2 testing and results disclosure would increase testing access. The BRCA Founder OutReach (BFOR) study is a prospective study of BRCA1/2 founder mutation screening among individuals of Ashkenazi Jewish descent that sought to involve participants' PCPs in results disclosure. We used quantitative and qualitative methods to evaluate PCPs' perspectives, knowledge, and experience disclosing results in BFOR. METHODS: Among PCPs nominated by BFOR participants to disclose BRCA1/2 results, we assessed the proportion agreeing to disclose. To examine PCP's perspectives, knowledge, and willingness to disclose results, we surveyed 501 nominated PCPs. To examine PCPs' experiences disclosing results in BFOR, we surveyed 101 PCPs and conducted 10 semi-structured interviews. RESULTS: In the BFOR study overall, PCPs agreed to disclose their patient's results 40.5% of the time. Two hundred thirty-four PCPs (46.7%) responded to the initial survey. Responding PCPs were more likely to agree to disclose patients' results than non-responders (57.3% vs. 28.6%, p<0.001). Among all respondents, most felt very (19.7%) or somewhat (39.1%) qualified to share results. Among PCPs declining to disclose, insufficient knowledge was the most common reason. In multivariable logistic regression, feeling qualified was the only variable significantly associated with agreeing to disclose results (OR 6.53, 95% CI 3.31, 12.88). In post-disclosure surveys (response rate=55%), PCPs reported largely positive experiences. Interview findings suggested that although PCPs valued the study-provided educational materials, they desired better integration of results and decision support into workflows. CONCLUSION: Barriers exist to incorporating BRCA1/2 testing into primary care. Most PCPs declined to disclose their patients' BFOR results, although survey respondents were motivated and had positive disclosure experiences. PCP training and integrated decision support could be beneficial. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03351803), November 24, 2017.
Authors: Louise Wideroff; Andrew N Freedman; Lorayn Olson; Carrie N Klabunde; William Davis; Kadaba P Srinath; Robert T Croyle; Rachel Ballard-Barbash Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-04 Impact factor: 4.254
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2019-08-20 Impact factor: 56.272
Authors: Cathelijne H van der Wouden; Deanna Alexis Carere; Anke H Maitland-van der Zee; Mack T Ruffin; J Scott Roberts; Robert C Green Journal: Ann Intern Med Date: 2016-03-01 Impact factor: 25.391
Authors: J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: A N Freedman; L Wideroff; L Olson; W Davis; C Klabunde; K P Srinath; B B Reeve; R T Croyle; R Ballard-Barbash Journal: Am J Med Genet A Date: 2003-07-01 Impact factor: 2.802
Authors: Katherine Kolor; Zhuo Chen; Scott D Grosse; Juan L Rodriguez; Ridgely Fisk Green; W David Dotson; M Scott Bowen; Julie A Lynch; Muin J Khoury Journal: MMWR Surveill Summ Date: 2017-09-08
Authors: Lydia E Pace; Yeonsoo S Lee; Nadine Tung; Jada G Hamilton; Camila Gabriel; Sahitya C Raja; Colby Jenkins; Anthony Braswell; Susan M Domchek; Heather Symecko; Kelsey Spielman; Beth Y Karlan; Jenny Lester; Daniella Kamara; Jeffrey Levin; Kelly Morgan; Kenneth Offit; Judy Garber; Nancy L Keating Journal: BMC Med Res Methodol Date: 2020-08-17 Impact factor: 4.615
Authors: Kelly M Morgan; Jada G Hamilton; Heather Symecko; Daniella Kamara; Colby Jenkins; Jenny Lester; Kelsey Spielman; Lydia E Pace; Camila Gabriel; Jeffrey D Levin; Prince Rainier Tejada; Anthony Braswell; Vanessa Marcell; Temima Wildman; Bryan Devolder; Robin Camhi Baum; Jeremy N Block; Yuri Fesko; Kylin Boehler; Victoria Howell; Jacob Heitler; Mark E Robson; Katherine L Nathanson; Nadine Tung; Beth Y Karlan; Susan M Domchek; Judy E Garber; Kenneth Offit Journal: Genet Med Date: 2021-12-03 Impact factor: 8.864